Comparative Analysis of Mitochondrial Peptides

The Major Mitochondrial Peptides

These peptides get grouped together, but their evidence is very uneven. SS-31 is now a prescription medicine for one rare disease, while MOTS-c rests mostly on mouse studies and humanin on cell work.

MOTS-c

• Origin: Encoded in mitochondrial DNA
• Size: 16 amino acids
• Primary Target: AMPK pathway
• Focus: Metabolic regulation; called an "exercise mimetic" based on mouse work

SS-31 (Elamipretide)

• Origin: Synthetic design
• Size: 4 amino acids (tetrapeptide)
• Primary Target: Cardiolipin in mitochondria
• Focus: Mitochondrial structure and function; approved as Forzinity for Barth syndrome

Humanin

• Origin: Encoded in mitochondrial DNA
• Size: 24 amino acids
• Primary Target: Multiple pathways
• Focus: Cell survival; first described in 2001 as protecting cultured neurons from Alzheimer's-related death

Mechanism Comparison

How Each Works

Pathway Illustration

MOTS-c -> AMPK -> Metabolic effects, fat oxidation
SS-31 -> Cardiolipin -> ETC efficiency, reduced ROS
Humanin -> Multiple -> Cytoprotection

These pathways come from lab work; none has been traced in people.

Athletic Applications Comparison

No study has tested any of these peptides for athletic performance in people.

Studied and Reported Uses

Performance Evidence

There's no human data to rank these peptides for endurance or recovery. In Barth syndrome, knee-extensor strength rose during an open-label extension but not during the 12-week randomized phase (FDA Drug Trials Snapshot). In mice, MOTS-c prevented diet-induced obesity; whether that carries over to people is unknown.

Practical Comparison

Dosing

These doses are reported, not recommended.

User SS-31 doses are a small fraction of the label dose, so the trials say little about them.

Availability and Cost

Research Status

Development Stage (as of October 2026)

Evidence Quality

In SPIBA-201, the 12-patient Barth trial behind the approval, elamipretide wasn't better than placebo on its primary endpoints (6-minute walk and fatigue); FDA approved it on knee strength and requires a confirmatory trial. MMPOWER-3 (mitochondrial myopathy) and ReCLAIM-2 (dry AMD) also missed their primary endpoints.

Safety Comparison

Known Safety Profile

Risk Assessment

Nobody has followed healthy users for years (see long-term health implications).

Matching Research to Goals

By Primary Goal

By Athlete Type

Forum posts often pair MOTS-c with endurance sports and SS-31 with strength-sport recovery. No study has compared them in athletes.

As of October 2026, WADA's 2026 Prohibited List names MOTS-c under S4.4.1, prohibited at all times. SS-31 isn't named, and its status since FDA approval is unverified. More in why MOTS-c and SS-31 are off-limits in sport.

Stacking Considerations

Combining Mitochondrial Peptides

• MOTS-c + SS-31: theoretical synergy only; no study has combined them
• Different mechanisms, so overlap is unlikely on paper
• Cost adds up quickly

With Other Peptides

Cost and Product Quality

Value Assessment

No benefit has been measured in healthy people, so there's no honest way to rate value.

Practical Considerations

• Quality is the biggest unknown for research-use vials; see how synthesis affects purity
• Users often describe starting one peptide at a time to tell what caused a side effect
• Research-use SS-31 isn't the approved prescription product

What We Still Don't Know

As of October 2026, no peer-reviewed study has given native MOTS-c to humans. We also don't know whether Forzinity's strength benefit holds up in the confirmatory trial, or what SS-31 does at user doses.

Comparison table